Phase I-II RTOG Study (99-06) of Patients With Muscle-Invasive Bladder Cancer Undergoing Transurethral Surgery, Paclitaxel, Cisplatin, and Twice-daily Radiotherapy Followed by Selective Bladder Preservation or Radical Cystectomy and Adjuvant Chemotherapy
Author:
Publisher
Elsevier BV
Subject
Urology
Reference15 articles.
1. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocols 85-12;Tester;Int J Radiat Oncol Biol Phys,1993
2. Neoadjuvant combined modality therapy with possible organ preservation for invasive bladder cancer;Tester;J Clin Oncol,1996
3. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03;Shipley;J Clin Oncol,1998
4. The Initial Results in Muscle-Invading Bladder Cancer of RTOG 95-06: Phase I/II Trial of Transurethral Surgery Plus Radiation Therapy with Concurrent Cisplatin and 5-Fluorouracil Followed by Selective Bladder Preservation or Cystectomy Depending on the Initial Response
5. RTOG 97-06: initial report of a phase I/II trial of selective bladder-conservation employing TURB, twice-daily accelerated irradiation sensitized with cisplatin followed by adjuvant MCV combination chemotherapy;Hagan;Int J Radiat Oncol Biol Phys,2003
Cited by 165 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Bladder only versus bladder plus pelvic lymph node chemoradiation for muscle-invasive bladder cancer;Urologic Oncology: Seminars and Original Investigations;2023-07
2. Bladder-sparing approaches for muscle invasive bladder cancer: a narrative review of current evidence and future perspectives;Translational Andrology and Urology;2023-05
3. Trimodal organ‑preserving treatment of muscle‑invasive bladder cancer;Research and Practical Medicine Journal;2023-03-26
4. Approaches to Clinical Complete Response after Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Possibilities and Limitations;Cancers;2023-02-19
5. Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How (Should) We Do It? A Narrative Review;Journal of Clinical Medicine;2023-02-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3